Ketamine-Assisted Psychotherapy, Psychedelic-Assisted Psychotherapy and Internal Family Systems Therapy Explained
Psilocybin-Assisted Psychotherapy (PAP) FAQs
Ketamine-Assisted Psychotherapy (KAP) FAQs
Want to learn more more about Psychedelic-Assisted Psychotherapy and Ketamine-Assisted Psychotherapy?
Below are some helpful research articles that dive in to these topics further.
Safety of Psychedelic-Assisted Psychotherapy (psilocybin)
- Freitas, R. R., Gotsis, E. S., Gallo, A. T., Fitzgibbon, B. M., Bailey, N. W., & Fitzgerald, P. B. (2025). The safety of psilocybin-assisted psychotherapy: A systematic review. Australian & New Zealand Journal of Psychiatry — journal link. This is a strong, current, directly on-point citation: 24 studies reviewed, common adverse events were things like elevated blood pressure, headache, nausea, and transient anxiety; no deaths attributed to psilocybin; the review’s own conclusion is “cautious optimism” given the preliminary, heterogeneous nature of the data — a fair, honest characterization worth matching in your own copy.
- A larger, newer adverse-event review for more depth: ScienceDirect systematic review, 42 studies/1,068 participants, concluding psilocybin “appears to have a favourable safety profile when administered in controlled settings.”
Ketamine-Assisted Psychotherapy research
- A good current, single link with breadth: Journey Clinical’s curated KAP research library — 30+ studies on ketamine for depression, PTSD, anxiety, addiction, updated regularly.
